Preface

Current Cancer Therapy Reviews (CCTR) will now publish its 18th volume. I have been the Editor-in-Chief of CCTR for over 2 years, and I am grateful to all contributors for making CCTR an informative journal for researchers in the field of cancer therapy over the years.

The previous year, much like the one before was affected by the COVID-19 pandemic. We have seen the continued use of vaccinations to control infections, and scientists around the world have taken the opportunity to gather precious data on the effect of SARS-COV-2 on patients who are accompanied by a variety of medical conditions. The information obtained from COVID-19 research can help improve cancer therapy.

We look forward to reviewing information on cancer therapy and COVID-19 this year. In the first of articles covering this topic, CCTR will be publishing a study of the lung epithelium in patients with COVID-19 and lung cancer co-morbidities. The journal will also present information on the effect of *Ziziphus mauritiana* extracts on human A549 lung cancer cell lines. In addition to covering these updates on lung cancer, CCTR will also be reporting on updates in pancreatic cancer, hepatocellular carcinoma, and some interesting reviews on natural products and anti-cancer targets in signal transduction pathways.

Once again, I am grateful to the authors, reviewers, and the Bentham Science staff for assisting with the publication of the new CCTR volume. I also welcome researchers, both young and experienced, from all over the globe to share their insights on cancer therapy to our editorial board.

With best wishes for 2022

Yangchao Chen  
(Editor-in-Chief)  
School of Biomedical Sciences  
Faculty of Medicine  
The Chinese University of Hong Kong  
Shatin  
Hong Kong  
E-mail: yangchaochen@cuhk.edu.hk